NCT02086552View on ClinicalTrials.gov

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

PHASE2CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

January 17, 2014

Primary Completion Date

January 15, 2018

Study Completion Date

August 13, 2021

Conditions

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

DRUG

Sonidegib

Given PO

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Mayo Clinic

OTHER